Business
Share Option Exercise and Issue of Equity
Share Option Exercise and Issue of Equity.
About this update from Theracryf Plc
[{"type":"text","content":"\n \nRNS Number : 6039Z Evgen Pharma PLC 21 May 2019 \n\nFor immediate release \n \nEvgen Pharma plc\n \n(\"Evgen\" or \"the Company\")\n \nShare option exercise and issue of equity \n \n \nEvgen (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that it has received notice to exercise options over 321,600 ordinary shares in the Company. \nOptions over 321,600 shares were exercised pursuant to grants under individual option agreements with an exercise price of 0.875p per share. Accordingly, the Company has issued and allotted 321,600 new ordinary shares of 0.25 pence each (\"New Ordinary Shares\"). The New Ordinary Shares rank pari passu with the Company's existing issued ordinary shares. Application has been made to admit the New Ordinary Shares to trading on AIM and dealings in these shares are expected to commence at 8.00 a.m. on 24 May 2019. \nThere are no shares held in treasury, therefore following the admission of the New Ordinary Shares the total number of voting rights in the Company will be 132,646,263. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest under the Disclosure and Transparency Rules.\n \nEnquiries:\n \n\n\n\nEvgen Pharma plc \nDr Stephen Franklin, CEO \nRichard Moulson, CFO\nwww.evgen.com\n\n\n \nc/o +44 (0) 20 7466 5000\n\n\n\n\nfinnCap\nGeoff Nash, Teddy Whiley (Corporate Finance)\nAlice Lane, Manasa Patil (ECM)\nwww.finncap.com\n\n\n+44 (0) 20 7220 0500\n\n\n\n\nWG Partners LLP\nNigel Barnes, Claes Spång \n\n\n+44 (0) 20 3705 9330\n\n\n\n\nBuchanan\nMark Court, Sophie Wills, Tilly Abraham\[email protected]\n \n\n\n+44 (0) 20 7466 5000\n\n\n\nAbout Evgen Pharma plc\nEvgen Pharma is a clinic...